105 related articles for article (PubMed ID: 7634047)
1. Multiple drug resistance in osteosarcoma.
Rosier RN; Teot LA; Hicks DG; Schwartz C; O'Keefe RJ; Puzas JE
Iowa Orthop J; 1995; 15():66-73. PubMed ID: 7634047
[No Abstract] [Full Text] [Related]
2. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
4. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance and malignancy in human osteosarcoma.
Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
[TBL] [Abstract][Full Text] [Related]
6. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.
Schwartz CL; Gorlick R; Teot L; Krailo M; Chen Z; Goorin A; Grier HE; Bernstein ML; Meyers P;
J Clin Oncol; 2007 May; 25(15):2057-62. PubMed ID: 17513810
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the expression of insulin-like growth factor I receptors and apoptosis after preliminary chemotherapy, in child and adolescent osteosarcoma].
Rytwiński K; Wnuk A; Woźniak W; Rychłowska M
Med Wieku Rozwoj; 2004; 8(2 Pt 1):267-73. PubMed ID: 15738602
[TBL] [Abstract][Full Text] [Related]
8. [Expression of multidrug resistance-associated protein 1 in osteosarcoma and its relationship with clinicopathologic characteristics].
Tu C; Tian Y; Pei F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):684-7. PubMed ID: 14619581
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
Suto R; Abe Y; Nakamura M; Ohnishi Y; Yoshimura M; Lee YH; Imanishi T; Yamazaki H; Kijima H; Tokunaga T; Oshika Y; Hiraoka N; Tamaoki N; Fukuda H; Ueyama Y
Int J Oncol; 1998 Feb; 12(2):287-91. PubMed ID: 9458350
[TBL] [Abstract][Full Text] [Related]
10. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.
Baldini N; Scotlandi K; Barbanti-Bròdano G; Manara MC; Maurici D; Bacci G; Bertoni F; Picci P; Sottili S; Campanacci M
N Engl J Med; 1995 Nov; 333(21):1380-5. PubMed ID: 7477118
[TBL] [Abstract][Full Text] [Related]
11. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
12. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients.
Pratt CB; Epelman S; Jaffe N
Cancer Treat Rep; 1987 Apr; 71(4):421-3. PubMed ID: 2435408
[No Abstract] [Full Text] [Related]
13. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and multidrug resistance.
Mesa-Tejada R
N Engl J Med; 1996 May; 334(20):1335-6; author reply 1336-7. PubMed ID: 8609959
[No Abstract] [Full Text] [Related]
15. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.
Song WS; Jeon DG; Kong CB; Cho WH; Koh JS; Lee JA; Yoo JY; Jung ST; Shin DS; Lee SY
Ann Surg Oncol; 2011 Jun; 18(6):1710-6. PubMed ID: 21222166
[TBL] [Abstract][Full Text] [Related]
16. Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
Bacci G; Ferrari S; Ruggieri P; Biagini R; Fabbri N; Campanacci L; Bacchini P; Longhi A; Forni C; Bertoni F
Acta Orthop Scand; 2001 Apr; 72(2):167-72. PubMed ID: 11372948
[TBL] [Abstract][Full Text] [Related]
17. [Histopathological study of the effect of preoperative chemotherapy on osteosarcoma].
Hayashi K
Nihon Seikeigeka Gakkai Zasshi; 1994 Apr; 68(4):151-61. PubMed ID: 8189097
[TBL] [Abstract][Full Text] [Related]
18. Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line.
Wang Z; Xia Q; Cui J; Diao Y; Li J
Oncol Rep; 2014 Jun; 31(6):2720-6. PubMed ID: 24788927
[TBL] [Abstract][Full Text] [Related]
19. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
[TBL] [Abstract][Full Text] [Related]
20. Association between P-glycoprotein expression and response to chemotherapy in patients with osteosarcoma: a systematic and meta-analysis.
Zhao ZG; Ding F; Liu M; Ma DZ; Zheng CK; Kan WS
J Cancer Res Ther; 2014 Nov; 10 Suppl():C206-9. PubMed ID: 25450283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
